Lauren Riker - Mar 10, 2022 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role
Senior Vice President, Finance
Signature
/s/ Kristen Williams, Attorney-in-Fact
Stock symbol
PCRX
Transactions as of
Mar 10, 2022
Transactions value $
-$561,798
Form type
4
Date filed
3/14/2022, 05:00 PM
Previous filing
Jan 20, 2022
Next filing
Jun 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCRX Common Stock Options Exercise $101K +9.3K +61.38% $10.81 24.5K Mar 10, 2022 Direct
transaction PCRX Common Stock Sale -$598K -8.4K -34.35% $71.14 16.1K Mar 10, 2022 Direct F1
transaction PCRX Common Stock Sale -$64.8K -900 -5.61% $71.95 15.2K Mar 10, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCRX Stock Option (Right to Buy) Options Exercise $0 -9.3K -100% $0.00* 0 Mar 10, 2022 Common Stock 9.3K $10.81 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.84 to $71.74, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 1 and 2.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.895 to $72.005, inclusive.
F3 The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months.